3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
3
Melanoma
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Virus Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Disease
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled